Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NSC001 in Mild to Moderate Alzheimer's Disease
NCT06995573Phase 2Recruiting
- Sponsor
- NSC Therapeutics
- Start
- Aug 2025
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of NGX267 in Alzheimer's disease (AD), sponsored by NSC Therapeutics. Started Aug 2025; status: recruiting.
02
Drugs
NGX267
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06995573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06995573.